INTRODUCTION
Regulation by p53 of a wide variety of its target genes contributes to the type and sensitivity of cellular response to different forms of stress (Bates and Vousden, 1999; Laptenko and Prives, 2006; Levine, 1997; Prives and Hall, 1999; Vogelstein et al., 2000) . It is likely that unique sets of p53-regulated genes are responsible for different outcomes, such as cell cycle arrest, senescence, or apoptosis, in response to distinct stimuli. Several models have been proposed to explain p53 selection of its target promoters.
Activation of distinct promoters and ensuing apoptosis are at least partially determined by the overall level of p53 protein (Chen et al., 1996; Ludwig et al., 1996; Ronen et al., 1996) , posttranslational modifications of p53 including phosphorylation (e.g., Ser46), acetylation and methylation (Appella and Anderson, 2001; Bode and Dong, 2004; Brooks and Gu, 2003; Chuikov et al., 2004; Huang et al., 2006) , and interaction with proteins such as ASPP1/2 (Samuels- Lev et al., 2001) , JMY (Shikama et al., 1999) , Mdm2 (Minsky and Oren, 2004; Ohkubo et al., 2006) , or other p53 family members (Flores et al., 2002) . While these may partially explain the molecular mechanism of p53 promoter discrimination, this phenomenon is still incompletely understood.
We used a multifaceted experimental approach that couples chromatin immunoprecipitation (ChIP) with sizefractionation by sucrose gradient ultracentrifugation and mass spectrometry to isolate functionally distinct promoter-bound p53 assemblies in vivo. This led to the identification of hCAS/CSE1L as a component of some chromatin-bound p53 transcriptional complexes. The cellular apoptosis susceptibility gene (hCAS) is the human homolog of the essential yeast chromosome segregation gene 1 (Cse1; Brinkmann et al., 1995; Xiao et al., 1993) . hCAS/CSE1L was originally identified in a screen for genes that render breast cancer cells resistant to apoptosis after certain treatments (Brinkmann et al., 1995; Xiao et al., 1993) . Expression of mutant yeast Cse1 was shown to cause defects in chromosome segregation and B-type cyclin degradation (Irniger et al., 1995; Xiao et al., 1993 ). hCAS/CSE1L was then shown to function as a specific nuclear transport factor to regulate Importin-a (Kap60p) transfer from the nucleus to the cytoplasm in human cells (Kutay et al., 1997) . A screen in yeast for boundary proteins that prevent the spread of heterochromatin and silencing of the HML locus identified several components of the nuclear pore complex and transport factors, including Cse1 (Ishii et al., 2002) . Indeed, a number of nuclear-cytoplasmic transport proteins are associated with discrete sets of transcribed genes which may be repositioned to the nuclear pore (Casolari et al., 2004) . hCAS/CSE1L is highly expressed in proliferating human cells, suggesting that it can play multiple roles in addition to apoptosis (Brinkmann et al., 1995) . Our results implicate a functional interaction between hCAS/CSE1L and the p53 tumor suppressor protein leading to critical changes in the p53 response.
RESULTS

Fractionation of p53-Containing Complexes Associated with Chromatin
To separate and isolate different promoter-bound p53 protein assemblies, cell extracts from formaldehyde crosslinked or untreated H1299 cells expressing adenovirally transduced p53 (Ad-p53; Figure 1A ) or tetracycline-regulated p53 that is expressed at physiological levels (Chen et al., 1996; Menendez et al., 2006 ; Figure 1B ) were subjected to sucrose gradient ultracentrifugation. In untreated cell lysates (À), p53 was detected primarily in the more slowly sedimenting fractions, while p53 from formaldehyde crosslinked cells (+) sedimented broadly through the gradient, indicating its participation in multiple crosslinkable complexes in vivo ( Figure 1A ). The distribution of actin indicated that p53 sedimention was not due to nonspecific crosslinking or protein aggregation ( Figure 1B ). ChIP analysis showed p53 association with p21 and HDM2 promoters in both intermediately and rapidly sedimenting gradient fractions, while p53 at PIG3 and p53AIP1 promoters was exclusively in the most rapidly sedimenting fractions ( Figure 1C ). PCR analysis of DNA from intermediate and rapidly sedimenting fractions (#11 and #17) performed with the above and two additional p53 targets, BAX and PUMA, again revealed two general size classes of promoters bound by p53 ( Figure 1D ). Thus, distinct promoter-bound p53 multiprotein complexes can be separated by size-fractionation.
Identification of hCAS/CSE1L within p53-Containing Crosslinked Complexes
Sucrose gradient fractionated fractions #7, 11, and 17 from crosslinked cells were immunoprecipitated using anti-p53 monoclonal antibodies followed by SDS-PAGE and silver staining ( Figure S1 ). Several polypeptides were identified by mass spectrometry that were unique to these fractions. Six matching peptides from the cellular apoptosis susceptibility protein (hCAS/CSE1L) were present in one minor unique band excised from the heavier p53-associated fraction #17 ( Figures 1E and S1 ) that was not in the intermediate (#11) or slower (#7) sedimenting fractions. The yeast homolog of hCAS/CSE1L was shown to have a direct role in regulation of gene expression, thus prompting us to examine the possible relationship of hCAS/CSE1L to p53.
Coassociation of p53 and hCAS/CSE1L in Human Cell Lines hCAS/CSE1L protein could be detected in immunoprecipitates of Ad-p53 from extracts of crosslinked H1299 cells, and a weak signal above background was even detected in uncrosslinked cell lysates (Figure 2A ). The specificities of anti-hCAS/CSE1L antibodies and siRNAs used in our experiments are shown in Figures S2, S3 , and S5. Importantly, when crosslinked sonicated cell extracts were subjected to sucrose gradient sedimentation as in Figure 1 , hCAS/CSE1L coimmunoprecipitated with p53 in the rapidly sedimenting fraction (#17), but not in the intermediate sedimenting fraction (#11; Figure 2B ). In fact, the sucrose gradient sedimentation profile of hCAS/CSE1L was similar to that of p53, further indicating that the two proteins were present together in a subset of their respective crosslinkable complexes ( Figure S2B ).
To investigate the interaction between endogenously expressed p53 and hCAS/CSE1L, MCF-7 cells harboring wild-type p53 were either left untreated (control) or treated with adriamycin and then crosslinked with formaldehyde. Endogenous hCAS/CSE1L was detectable within anti-p53 immunoprecipitates, and this was markedly augmented when p53 levels were increased following DNA damage ( Figure 2C ). Reciprocally, p53 could be detected in immunoprecipitates of hCAS/CSE1L in lysates of either H1299 cells expressing ectopic p53 ( Figure 2D ) or MCF-7 cells expressing endogenous p53 after adriamycin treatment ( Figure 2E ). Since hCAS/CSE1L could not be detectably coimmunoprecipitated with ectopically expressed HAtagged E2F1 from crosslinked H1299 cell extracts, it does not associate with all mammalian transcription factors ( Figure 2F ).
Levels of hCAS/CSE1L Affect Induction of Select p53 Target Genes and Apoptosis
The effect of hCAS/CSE1L downregulation on p53 transcriptional activity was examined by transfecting MCF-7 cells with either hCAS/CSE1L RNAi or control RNAi for 48 hr after which cells were either untreated or treated with camptothecin (CPT) for 16 hr. Although hCAS/ CSE1L protein levels were significantly reduced by hCAS/CSE1L RNAi, p53 protein levels were unaffected ( Figure 3A ). While reducing hCAS/CSE1L had virtually no effect on protein levels of HDM2 and only a modest effect on the accumulation of p21 protein, there was a significant inhibition of PIG3 protein accumulation following DNA damage. Similar results were obtained with H1299 cells infected with adenoviruses expressing either LacZ or p53 ( Figure S4A ). A concentration range of two different hCAS/CSE1L RNAi sequences (#2 and #3) caused proportionate levels of reduction of both hCAS/CSE1L and PIG3, again with negligible effects on p21 or p53 ( Figure S5 ).
In line with these results PIG3 mRNA induction by p53 was significantly suppressed after hCAS/CSE1L downregulation with little effect on p21 mRNA induction ( Figure 3B ). Additionally, p53 induction of p53AIP1 and p53R2 mRNAs was also significantly reduced by hCAS/ CSE1L silencing, whereas 14-3-3s and PUMA were not affected. Similar results were obtained using H1299 cells expressing ectopic p53 ( Figure S4B ). PIG3, PUMA, and p53AIP1 are proapoptotic proteins, while p21, p53R2, and 14-3-3s are not. Therefore, responses to hCAS/ CSE1L downregulation were neither exclusive to proapoptotic genes nor did all proapoptotic targets require hCAS/CSE1L for full expression. Nonetheless, in conjunction with our observations that hCAS/CSE1L was found associated with p53 only in the most rapidly sedimenting complexes, these data indicate that hCAS/CSE1L plays a role in regulating expression of a specific subset of p53 target genes.
Since at least two proapoptotic target genes were reduced by hCAS/CSE1L downregulation, we examined whether reduced levels of hCAS/CSE1L affect DNA damage-induced apoptosis. When MCF-7 cells were transfected with control RNAi (Luciferase RNAi) or two (A) Sucrose gradient centrifugation fractionation of p53 complexes. H1299 cells were infected with a recombinant adenovirus expressing wild-type p53 (30 MOI) and then were treated or not with formaldehyde as indicated (Crosslink + or À) prior to extraction and sonication as described in Experimental Procedures. Extracts (2.5 mg protein) were then subjected to ultracentrifugation through a 10%-40% sucrose gradient. Collected gradient fractions were reverse crosslinked and then 20 ml of each fraction were subjected to immunoblotting with anti-p53 antibody (DO1). (B) Fractionation of p53 complexes after DNA damage in H1299 cells expressing tetracycline-regulated p53. p53 in H24-14 cells clonally derived from H1299 cell line was induced by removal of tetracycline for 24 hr, and then cells were first treated with adriamycin (3 mM) for 16 hr and then treated or not with formaldehyde prior to extraction and sonication. Sucrose gradient centrifugation and immunoblotting with anti-p53 (DO1) and anti-actin antibodies were performed as in (A). (C) ChIP profiling of size-fractioned p53 chromatin complexes. Crosslinked cell extracts were subjected to sucrose gradient sedimentation and fractionation as in (A). Upper panel: Anti-p53 immunoblot with 20 ml of each gradient fraction. Lower panels: ChIP analysis; each sucrose fraction (500 ml) was immunoprecipitated with anti-p53 antibodies (DO1/ 1801), then input (first lanes) and immunoprecipitated DNA from each fraction were purified and subjected to PCR to detect p53 associated with p53 target gene promoters as described in Experimental Procedures. PIG3 À318 refers to canonical p53 binding site at À328/À309 in the PIG3 gene (see Figure 5A ). DNA size markers are in second lanes. (D) ChIP profiling of target genes associated with intermediate or high-molecular-weight p53 complexes. ChIP analysis was performed using fractions (Fr) #11 and #17 of a sucrose gradient as in (A) from cells infected with recombinant adenoviruses expressing either LacZ or p53 using primers spanning p53 binding sites within the indicated p53 target genes. Representative images are shown in left panel. PCR products were quantified using Kodak gel imaging software, and quantification representing the average of three independent experiments is shown in right panel. Input lanes were from the p53-expressing samples. (E) hCAS/CSE1L sequence. Isolation and identification of hCAS/CSE1L polypeptide from p53-associated rapidly sedimenting crosslinked protein complexes are described in Experimental Procedures and Figure S1 . Sequence of hCAS/CSE1L is shown with underlined matched peptide sequences identified by mass spectrometry.
hCAS/CSE1L siRNAs (#2 or #3; see Figure S5 ) and then treated or not with UVC radiation, the ensuing apoptosis was less than half of that seen with the control siRNA ( Figure 3C ). Confirming a previous report (Latonen and Laiho, 2005) , UVC-induced cell death was greatly reduced when p53 was silenced ( Figure S6 ). Thus, extending earlier findings for a role for hCAS/CSE1L in some types of apoptosis (Brinkmann et al., 1995 (Brinkmann et al., , 1996 , hCAS/CSE1L facilitates cell death caused by a form of stress that is linked to the regulation and function of p53.
hCAS/CSE1L Binds to Select p53 Target Genes In Vivo
We determined whether hCAS/CSE1L itself associates with p53 target promoters. The primary amino acid sequence of hCAS/CSE1L suggests two potential DNAinteracting domains, one a short basic region within residues 372-385 that was predicted to both contain a nuclear localization signal as well as a possible DNA-binding module, and the second a potential zinc finger motif (His-Xaa2-His-Xaa6-Cys-Xaa6-Cys) within amino acids 613-630 ( Figure 4A ; Brinkmann et al., 1995) . The basic region of hCAS/CSE1L is highly conserved from yeast to humans, whereas the putative zinc finger motif region is less well conserved ( Figure 4B ). Vectors expressing either FLAG-tagged wild-type hCAS/CSE1L or mutant versions deleting either the basic region (D372-385/hCAS) or zinc finger motif (D613-630/hCAS) were introduced into U2OS cells ( Figure 4A ). Protein levels of either hCAS/ CSE1L deletion mutant were consistently lower than wild-type hCAS/CSE1L ( Figure 4C , upper panel). When anti-FLAG antibody (M2) was used to measure Figure 1A were immunoprecipitated with anti-p53 DO1/1801 Protein G Sepharose beads followed by SDS-PAGE and immunoblotting with anti-hCAS/CSE1L (upper panel) and anti-p53 DO1 (lower panel) antibodies. (C) hCAS/CSE1L associates with endogenously expressed p53. MCF-7 cells were treated or not with adriamycin (2 mM) for 16 hr and then immunoprecipitated with anti-p53 DO1/1801 Protein G Sepharose beads prior to SDS-PAGE and immunoblotting with anti-hCAS/CSE1L (upper panel) and anti-p53 DO1 (lower panel) antibodies. Input represents 5% of total lysate. (D and E) p53 is present in anti-hCAS/CSE1L immunoprecipitates. H1299 cells infected with p53 or LacZ adenoviruses (D) or MCF-7 cells treated or not with adriamycin (2 mM) for 16 hr (E) were then treated with formaldehyde prior to extraction and sonication. Extracts were then immunoprecipitated with anti-hCAS/CSE1L (hCAS #689/#692) or control IgG coupled to Protein G Sepharose beads followed by SDS-PAGE and immunoblotting (IB) with anti-hCAS/CSE1L (upper panel) and anti-p53 DO1 (lower panel). Inputs represent 5% of total lysate. (F) hCAS/CSE1L does not associate with E2F1. H1299 cells were transfected with a construct expressing HA-E2F1 for 24 hr and then treated with formaldehyde prior to extraction and sonication. Extracts were then immunoprecipitated with anti-HA Protein G Sepharose beads followed by SDS-PAGE and immunoblotting (IB) with anti-hCAS/CSE1L (upper panel) and anti-HA antibody (lower panel).
Figure 3. hCAS/CSE1L Regulates Induction of Select p53 Target Genes and Apoptosis
(A) Selective effects of hCAS/CSE1L downregulation on p53 target protein levels in MCF-7 cells. Cultures were transfected with luciferase siRNA (control RNAi) or hCAS/CSE1L siRNA (hCAS RNAi #1) for 48 hr, and then cells were either not treated (control) or treated with CPT for 16 hr. Cell extracts (20 mg) were resolved by SDS-PAGE and subjected to immunoblotting with antibodies against hCAS/CSE1L (hCAS 30F12), p53 (DO1), HDM2, p21, PIG3, or Actin as indicated. (B) hCAS/CSE1L downregulation reduces expression of select p53 target genes. MCF-7 cells were transfected with luciferase siRNA (control RNAi) or hCAS/CSE1L siRNA (hCAS RNAi #1) as in (A). Total RNA was subjected to real-time RT-PCR analysis. Expression levels of actin, hCAS/CSE1L, p53, p21, 14-3-3s, PUMA, p53R2, PIG3, and p53AIP1 RNAs were determined by the comparative threshold cycle method. (C) hCAS/CSE1L downregulation protects MCF-7 cells from apoptosis. MCF-7 cells were transfected with luciferase siRNA (control RNAi) or two different hCAS/CSE1L siRNAs (hCAS RNAi #2) or (hCAS RNAi #3) for 48 hr, and then cells were either not treated (Untreated) or treated with UVC radiation (UVC 20 J/m 2 ) for 36 hr. Left Panel: Cells were collected, fixed in cold methanol, and subjected to FACS analysis. Upper right panel: Immunoblotting of hCAS/CSE1L in extracts of parallel cultures treated with control or hCAS/CSE1L siRNAs #2 and #3. Lower right graph: Percent of cells with sub-G0/G1 DNA content after treatment with or without UVC with either control siRNA or hCAS/CSE1L siRNAs #2 or #3. The average of three independent experiments is shown with error bars indicating standard deviation.
association of ectopic wild-type hCAS/CSE1L with the p53 binding site at À318 within the PIG3 promoter, there was a strong signal over the vector control ( Figure 4C , lower panels). While binding by the putative zinc fingerdeleted version of hCAS/CSE1L was reduced (consistent with its lower levels), deletion of the basic region of hCAS/ CSE1L virtually abrogated the association of ectopic hCAS/CSE1L with the PIG3 promoter ( Figure 4C ). The inability of the D372-385/hCAS mutant to associate with chromatin is not due to a nuclear localization defect ( Figure S7 ), suggesting that sequences within the basic region play a role in the association of hCAS/CSE1L with chromatin. We then performed ChIP assays with either H1299 cells infected with adenoviruses expressing p53 or MCF-7 cells that were either untreated or treated with camptothecin. Predictably, p53 was found associated with regions containing its binding sites within several promoters in H1299 cells (C) hCAS/CSE1L association with the PIG3 promoter is reduced by deleting residues 372-385. U2OS cells were transfected with empty vector, FLAG-tagged wild-type hCAS/ CSE1L (WT-hCAS), FLAG-tagged hCAS/ CSE1L lacking residues 372-385 or residues 613-630 (D372-385/hCAS and D613-630/ hCAS, respectively) for 24 hr. Upper two panels: aliquots of crosslinked and sonicated transfected cell extracts were used for immunoblotting with either anti-FLAG (M2) or antiactin antibodies. Lower two panels: A ChIP assay using anti-FLAG (M2) antibody was performed using same extracts of crosslinked cells transfected with FLAG-tagged wild-type or the two deletion mutants shown in (A) to detect association of hCAS/CSE1L with the PIG3 p53-binding-site (À318) region (PIG3 BS). GAPDH is shown as a negative control. (D and E) Autonomous association of hCAS/ CSE1L with select p53 target gene promoters. H1299 cells infected with LacZ or p53 (p53WT) adenoviruses for 24 hr (D) and MCF-7 cells either not treated or treated with CPT (300 nM) for 24 hr (E) were treated with formaldehyde prior to extraction and sonication. A ChIP assay was performed using anti-p53 (DO1/1801) or anti-hCAS/CSE1L antibodies (hCAS #689/#692) using primers to amplify sequences spanning p53 binding sites within the indicated p53 target gene promoters as described in Experimental Procedures. (F) hCAS/CSE1L and p53 are simultaneously present within the PIG3 promoter. H1299 cells infected with adenoviruses expressing ether LacZ or wild-type p53 for 24 hr were treated with formaldehyde prior to sonication and extraction. Extracts were first subjected to immunoprecipitation with anti-p53 (DO1/1801) or control IgG (ChIP), and then eluates were subjected to a subsequent immunoprecipitation with hCAS/CSE1L (hCAS #689/#692) antibodies or control IgG (ReChIP). In both cases DNA was recovered and amplified by PCR as described in Experimental Procedures.
expressing adenovirally transduced p53 but not LacZ ( Figure 4D ). In MCF-7 cells basal p53 binding to each of these promoters was increased after CPT treatment, undoubtedly related to the increased levels of p53 caused by treatment with this agent ( Figure 4E ). Endogenous hCAS/CSE1L was associated with PIG3, p53AIP1, and p53R2 promoters in both H1299 and MCF-7 cells, while the signal obtained with p21 and PUMA promoters was either very weak or undetectable ( Figures 4D and 4E) . Thus, there was a striking correlation between binding of hCAS/CSE1L uniquely to those promoters of p53 target genes (PIG3, p53AIP1, and p53R2) whose induction was reduced after hCAS/CSE1L downregulation. Unexpectedly, hCAS/CSE1L was also associated with these promoters in the absence of p53 in H1299 cells, showing that promoter binding by hCAS/ CSE1L is independent of p53 ( Figure 4D ).
To determine whether p53 and hCAS/CSE1L are concurrently associated with the PIG3 promoter, we performed a serial ChIP experiment ( Figure 4F ). As we were able to obtain robust and specific signals with both the ChIP and Re-ChIP fractions, p53 and hCAS/CSE1L are present at the PIG3 promoter at the same time within a crosslinkable complex. Nonetheless, despite their simultaneous presence, neither hCAS/CSE1L ( Figure 4D ) or p53 ( Figure 6A ) are required for the interaction of the other protein at the PIG3 promoter.
We examined in more detail hCAS/CSE1L and p53 association with the PIG3 promoter using real-time PCR ( Figure 5A ; see diagram indicating primer sets). Two separate binding sites for p53 within the PIG3 promoter have been identified. The first conforms to the canonical p53 binding sequence and is located at À328/À309 (Polyak et al., 1997) , and the second is within a microsatellite region at +442/+516 (Contente et al., 2002) . Peak binding signals for p53 were detected at both p53 binding sites, with significant signal also detected both between these sites, i.e., in the vicinity of nucleotide +223 and within a region approximately 500 bp upstream of the first binding site (À833). Little or no binding by p53 was detected approximately 1.7 kb upstream from the canonical p53 binding site (À1778). hCAS/CSE1L binding to the PIG3 promoter substantially differed from p53 in that it strongly associated both with the À318 and À813 regions but showed little or no association with regions within the transcribed sequence at +223 or the microsatellite zone (+509). Like p53, the signal at À1778 seen with hCAS/ CSE1L was negligible.
The p21 promoter also has two p53 binding sites at $À2.1 and $À1.3 kb, the 5 0 and 3 0 sites, respectively (Macleod et al., 1995) . hCAS/CSE1L did not associate with either 5 0 or 3 0 p53 binding sites in the p21 promoter ( Figure 5B) . Furthermore, ChIP analysis showed that hCAS/CSE1L did not associate with several regions within the PUMA locus in addition to its p53-binding-site region ( Figure S8A ).
hCAS/CSE1L and p53 Coregulate Methylation of Lysine 27 on Histone H3 Chromatin domains that are involved in establishment of heterochromatin boundaries and epigenetic gene (A) ChIP scanning of p53 or hCAS/CSE1L at different PIG3 promoter regions. H1299 cells infected with a wild-type p53 adenovirus for 24 hr were treated with formaldehyde prior to sonication and extraction. Extracts of p53-expressing cells were subjected to a ChIP assay with anti-p53 (DO1/1801) or hCAS/ CSE1L (hCAS #689/#692) antibodies using real-time PCR using indicated primers shown on the map (top). (B) hCAS/CSE1L is not associated with p53 binding regions in the p21 promoter. H1299 cells were infected with adenoviruses expressing either LacZ or p53 (p53WT) for 24 hr and were treated as described in (A). A ChIP assay was performed using anti-p53 (DO1/1801), anti-hCAS/CSE1L antibodies (hCAS #689/ #692), or without antibody (no Ab), then input and immunoprecipitated DNA were purified and subjected to real-time PCR to quantify association with the PIG3 (À318) p53 binding site, the p21 5 0 (À2272) or the p21 3 0 (À1421) p53 binding sites.
regulation are defined by distinct sets of posttranslationally modified histones. Modification of histone H3 by acetylation at lysine 9 (K9) as well as methylation at lysine 4 (K4) is often suppressed in silenced heterochromatin and enriched in active euchromatin (Ehrenhofer-Murray, 2004; Kouzarides, 2002; Lachner et al., 2003) . In contrast, histone H3 methylation at K9 (K9M-H3) and K27 (K27M-H3) is enriched in regions of inactive heterochromatin (Ehrenhofer-Murray, 2004; Kouzarides, 2002; Lachner et al., 2003; Martin and Zhang, 2005; Sims et al., 2003) . Using H1299 cells expressing ectopic p53, we tested the impact of downregulation of hCAS/CSE1L by siRNA on histone H3 modifications within the PIG3 promoter at the À318 site that is associated with both p53 and hCAS/CSE1L ( Figure 6A ). ChIP analysis with specific antibodies against p53, hCAS/CSE1L, or with histone H3 methylation-specific antibodies (tri-K4M-H3, di-K9M-H3, and tri-K27M-H3) was performed. We confirmed that both hCAS/CSE1L and p53 binding to the PIG3 À318 region are independent of one another ( Figure 6A , top left panels). Little or no impact of reducing hCAS/CSE1L levels on either trimethylation of lysine 4 (tri-K4M-H3) or dimethylation of lysine 9 (di-K9M-H3) was detected ( Figure 6A , bottom left panels), while lysine 27 methylation (tri-K27M-H3), a repressive modification for gene transcription, was increased significantly at the region spanning the canonical p53 binding site on the PIG3 promoter when hCAS/CSE1L was downregulated ( Figure 6A , bottom right panel). We then examined: (1) a region relatively far upstream (À2149), (2) the previously examined p53-binding-site region (À318), (3) the second region within the coding sequence (+223) where we had detected a ChIP signal with p53 but not with hCAS/CSE1, and (4) a still further region within Intron 2 (+2483) downstream of the transcription start site ( Figure 6B ). While there was a relatively small impact of hCAS/CSE1L downregulation on K27 trimethylation at the far upstream (À2149) region, and there was again somewhat less K27 trimethylation in the vicinity of À318, remarkably, at +223 there was dramatically less K27 methylation in the presence of p53 when there were normal levels of hCAS/CSE1L, and this was substantially reversed when hCAS/CSE1L was downregulated. In fact, this was also seen at the far downstream (+2483) site. Thus, p53 expression leads to reduced K27 methylation within the transcribed region of the PIG3 gene, and this requires hCAS/CSE1L, even though hCAS/CSE1L does not itself interact with this region. Dimethylation of histone H3 K9 at both the À318 and +223 sites was not significantly affected by either downregulation of hCAS/CSE1L or the presence of p53 (data not shown). These data implicate hCAS/CSE1L as having a long-range effect on chromatin within a p53-regulated locus.
Trimethylation of histone H3 K27 at p53 binding sites within the p53R2 and p53AIP1 promoters to which hCAS/CSE1L binds ( Figure 6C , left and middle panels, respectively) as well as the same four regions within the PUMA promoter where we failed to detect hCAS/CSE1L association ( Figure S8 ) was also examined. With p53R2 we obtained essentially similar results as seen with PIG3 at À318-namely increased signal when hCAS/CSE1L was decreased and decreased signal when p53 was expressed which was partially restored by downregulation of hCAS/CSE1L. The results were less pronounced with the p53AIP1 promoter, although the tendency was the same. Note that the extent of K27 methylation at both p53AIP1 and p53R2 genes was markedly greater than seen at the PIG3 gene. By contrast there was no impact on a region within either the non-p53-regulated GAPDH promoter at +2182 ( Figure 6C, right panel) or several regions within the PUMA promoter, including near and far downstream regions ( Figure S8B ). In fact, there was very little K27 methylation at the downstream regions at the PUMA locus with or without p53.
Importantly, the impact of hCAS/CSE1L silencing on histone H3 tri-K27 methylation at sites within the PIG3 or p53AIP1 promoters in untreated or daunorubicin-treated U2OS cells that harbor endogenous p53 revealed a similar trend ( Figure S9 ). It is intriguing that within those genes to which hCAS/CSE1L binds we saw increased trimethylation of histone H3 K27 (albeit rather modest) without expression of p53. This effect likely requires an interaction of hCAS/CSE1L with the promoter because it was not seen within either GAPDH or PUMA genes.
Taken together, our data are consistent with the model shown in Figure 7 that hCAS/CSE1L coregulates select genes with p53 and the two proteins function together to facilitate the formation of active chromatin at select targets in human cells.
DISCUSSION
Our modified version of the ChIP protocol revealed that hCAS/CSE1L is uniquely present in high-molecularweight protein assemblies that interact with a subset of p53 target gene promoters in vivo. There are several different proteins exclusively present in intermediate and rapidly sedimenting sucrose gradient fractions ( Figure S1 ; data not shown), and so this approach should be useful for identification of other components of chromatin-associated complexes. Formaldehyde is a highresolution ($2 Å ) crosslinking agent. Although we cannot conclude that hCAS/CSE1L and p53 interact directly, they are likely to be associated in a functional complex that regulates gene expression. The approach described herein may be further exploited to demonstrate relationships between proteins that would be missed by more conventional immunoaffinity proteomic methods.
Deletion of a short basic region between amino acids 372 and 385 in hCAS/CSE1L abrogated its interaction with the PIG3 promoter in vivo ( Figure 4C ). To date, however, we have not been able to obtain evidence for significant binding of recombinant hCAS/CSE1L protein to naked DNA sequences spanning the regions of the PIG3 promoter that provided strong ChIP signals with anti-hCAS/CSE1L antibodies (unpublished data). Structures of yeast Cse1 Figure 6 . hCAS/CSE1L Levels Affect Histone H3 Lysine 27 Methylation (A) hCAS/CSE1L downregulation selectively affects histone H3 lysine methylation at the PIG3 p53 binding site. H1299 cells were transfected with control RNAi (Luciferase RNAi) or hCAS/CSE1L RNAi (hCAS RNAi #2) for 48 hr, and then cells were infected with adenoviruses expressing LacZ or wild-type p53 for 24 hr. ChIP assays were performed to examine association of p53, hCAS/CSE1L, or histone H3 modifications within the region of the PIG3 p53 binding site (À318) using antibodies directed against p53 (DO1/1801), hCAS/CSE1L (hCAS#689/#692), tri-K4M-H3, di-K9M-H3, and tri-K27M-H3. (B) Long-range effects of hCAS/CSE1L on histone H3 lysine K27 methylation. H1299 cells were treated as described in (A). ChIP assays were performed using real-time PCR to detect tri-K27M-H3 methylation status in the vicinity of the following regions: upstream p53 and hCAS/CSE1L have been solved with (Matsuura and Stewart, 2004) and without (Cook et al., 2005) its cargo Importin-a/Kap60p and Ran-GTP. Cse1 contains 20 HEAT (huntingtin, elongation factor 3, A subunit of PP2A and TOR) repeats, sequence features that are present in importins and exportins (Conti et al., 2006) . The hCAS/CSE1L region (amino acids 372-385) that we identified as being important for hCAS/CSE1L association with chromatin lies within a conserved hinge sequence that interrupts HEAT repeat 8 and bridges the RanGTP and Importin-a/Kap60p-interacting regions of Cse1. Perhaps this region, which in yeast Cse1 undergoes a conformational change dependent on binding to its cargo (Cook et al., 2005) , provides a surface for interaction either with chromatin or chromatin-associated proteins. Determining how hCAS/CSE1L associates with chromatin will be challenging, and we hope to obtain insight into this question in the future.
It is highly relevant that a number of yeast nuclear transport factors, including Cse1, associate with discrete sets of active genes and can regulate their activity and nuclear organization in yeast (Casolari et al., 2004; Feuerbach et al., 2002; Kosova et al., 2000; Strambio-de-Castillia et al., 1999) . Our results show that this can also occur in mammalian cells. Interestingly, like hCAS/CSE1L, two components of the nuclear pore complex (NPC), Nup98 and Importin-a2, can associate with the PIG3 but not the p21 or PUMA promoters ( Figure S10 ). This suggests the intriguing possibility that some p53-responsive genes may be in close association with the nuclear periphery or NPC. The selective regulation of p53 transcriptional activity by hCAS/CSE1L is likely achieved through association with p53 target gene promoters rather than through its function as a nuclear export factor because hCAS/ CSE1L downregulation had little or no impact on subcellular localization and accumulation of p53 after DNA damage ( Figure S3 ). It is likely that hCAS/CSE1L regulates genes other than p53 targets, given that its interactions with such targets are independent of p53. Future studies should provide a more global view of the genes with which hCAS/CSE1L associates and regulates.
Levels of hCAS/CSE1L affect trimethylation of histone H3 K27 at the PIG3 promoter without significant impact on H3 K9, another repressive modification. It is especially intriguing that the requirement for hCAS/CSE1L is much more pronounced when p53 is present and when PIG3 is being transcribed actively. Whether or not the specific mechanistic details by which hCAS/CSE1L blocks heterochromatinization in yeast and human cells are well conserved remains to be determined. A set of proteins, sometimes termed the EED-EZH2 complex, trimethylates histone H3 lysine 27 leading to recruitment or facilitation of the activity of a second group of proteins, the polycomb repressive complex 1 (PRC1; Cao and Zhang, 2004) . Possibly hCAS/CSE1L itself (or a hCAS/CSE1L-containing complex) prevents either the recruitment or activity of histone lysine 27 methylating enzymes. Alternately hCAS/CSE1L may augment K27 demethylase activity. These are important avenues for future studies.
Interestingly, a component of the histone H3 lysine 27 methylating complex, EZH2, like hCAS/CSE1L, is frequently present at supraphysiological levels in prostate cancers (Rhodes et al., 2003; Varambally et al., 2002) , possibly due to its regulation by the RB-E2F pathway. Perhaps abnormally high levels of EZH2 result in formation of negative binding site (À2149), the p53 binding site (À318), upstream transcribed region (+223), and downstream transcribed region in Intron 2 (+2483). The average of three experiments is shown with error bars indicating standard deviation. Shown above is a diagram of the PIG3 gene where head-tohead arrows indicate location of primer sets used in ChIPs, and nucleotide numbers refer to the center of the amplified region. The shaded area upstream of +1 refers to the potential hCAS/CSE1L binding region. p53 BS1 and p53 BS2 refer to p53 binding sites (p53 consensus BS and TGYCC 15 repeat region, respectively) as shown in Figure 5A . (C) hCAS/CSE1L downregulation affects histone H3 lysine K27 methylation within p53R2 and p53AIP1 promoters but not within the GAPDH gene. H1299 cells were treated and prepared as described in (A). ChIP assays were performed in which tri-K27M-H3 was assessed at p53 binding sites within the p53R2 (+2648) and p53AIP1 (+1968) promoters or at a site within the GAPDH gene (+2182) using real-time PCR. a nonfunctional EZH2 complex (Cao and Zhang, 2004) . Likewise, hCAS/CSE1L levels and activity may need to be tightly regulated. Of note, while under the conditions shown in Figure 3D hCAS/CSE1L RNAi reduces apoptosis caused by UVC, hCAS/CSE1L depletion, either by higher doses of RNAi or at longer times after RNAi treatment (approximately 4 to 5 days), leads to subsequent cell death in MCF-7 cells and HCT116 cells (data not shown). This is consistent with observations that mutant yeast Cse1 displays a conditional lethal phenotype, homozygous hCAS/CSE1L knockout mice are embryonic lethal, and antisense-mediated depletion of hCAS/CSE1L eventually results in cell death in HeLa cells (Ogryzko et al., 1997) . Given its multiple roles in nuclear transport, chromatin regulation, and cell death, it is likely that strict control of hCAS/CSE1L expression is a requirement for it to function effectively. Future studies will hopefully lead to a fuller understanding of this interesting protein and its relationship to p53.
EXPERIMENTAL PROCEDURES
Cell Culture, Drugs, and Plasmids H1299, MCF-7, 293, IMR90, and HCT116 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and antibiotics. H1299 cells expressing tetracyclineregulated p53 (clone H24-14) as previously described (Baptiste et al., 2002; Chen et al., 1996) were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA) containing 10% FBS, 250 mg/ml G418, 2.5 mg/ml puromycin, and 5 mg/ml tetracycline. To induce p53 in H24-14 cells, cultures were plated in media lacking tetracycline, G418, and puromycin and 24 hr later were washed twice in media lacking tetracycline. Adriamicin and camptothecin (Oncogene Research Products, San Diego, CA) were dissolved in DMSO. The coding sequence of an N-terminally His-tagged human hCAS/CSE1L in the pQE30 vector, kindly provided by Dr. Dirk Gorlich (Universitate Heidlberg, Heiderberg, Germany) was cloned into the NotI/BamH1 site of a 3xFLAG-CMV-7.1 mammalian expression vector (Sigma, St. Louis, MO) to generate 3xFLAG-hCAS/CSE1L. Constructs expressing deletion mutant forms of hCAS/CSE1L (D372-385/hCAS/CSE1L and D613-630/hCAS/CSE1L) were generated by oligonucleotide-directed mutagenesis (Quickchange, Stratagene) using the 3xFLAG-hCAS/ CSE1L plasmid. A construct expressing HA-tagged E2F1 was described previously (Urist et al., 2004) .
Western Blot Analysis and Antibodies
For protein analysis cells were harvested and subjected to immunoblotting as previously described (Urist et al., 2004) . The following primary antibodies were used to detect specific proteins. hCAS/ CSE1L: anti-hCAS 30F12 (Novocastra UK); p53: DO1 hybridoma supernatant; p21: anti-p21 (Ab-1; Oncogene Research); actin: anti-actin (Sigma); HDM2: anti-HDM2, IF2 (Oncogene Research); anti-PIG3 (polyclonal) and anti-FLAG M2 antibodies (Sigma).
Two hCAS/CSE1L polyclonal antibodies were also raised (Covance) against peptides corresponding to sequences within the N-terminus (KKTLDPDPAIRRPAEC; hCAS#692) or C terminus (CDDTIPDEEH FIDIED; hCAS#689). Crude rabbit serum was subjected to hCAS/ CSE1L affinity purification (a detailed protocol is available on request). Specificity of these antibodies is shown in Figure S2 .
Gene Transfer and RNA Interference
Recombinant adenoviruses encoding wild-type human p53 (p53WT) or b-galactosidase (LacZ) were propagated in 293 cells, and then viral titers were determined by a limiting dilution bioassay also using 293 cells. Infection of cells were performed by adding viral solutions to cell monolayers and incubating at 37 C for 60 min with brief agitation at the indicated multiplicity of infection (MOI). For RNAi experiments, 21 nucleotide siRNA duplexes with 3 0 dTdT overhangs corresponding to hCAS/CSE1L mRNA (hCAS RNAi #1, AAGCCAACATAGTGCACT TGA; hCAS RNAi#2, AACCCTGCTGCTGTTGTAAAT; hCAS RNAi#3, AACGGGTCAAGAGGTTAAATA) were synthesized by QIAGEN Inc.
(Valencia, CA). The sequence for control RNAi corresponding to firefly luciferase mRNA was described previously (Urist et al., 2004) . MCF-7 cells or H1299 cells were plated at 30%-40% confluency and transfected with the indicated siRNA oligonucleotide (50 nM) using Dharmafect 1 (Dharmacon, Lafayette, CO). After 24 hr the cells received a second dose of siRNA after which they were either left untreated or exposed to camptothecin (CPT; 300 nM) and infected with recombinant adenoviruses prior to lysis. For transfection of plasmids, H1299 cells were plated at greater than 80% confluency and transfected with up to 5 mg of DNA with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) at a DNA:lipid ratio of 1:1.2.
Chromatin Immunoprecipitation Assay H1299 or MCF-7 cells (each two 10 cm plates) were washed once in 13 phosphate-buffered saline (PBS) and then treated with 1% formaldehyde in PBS at 37 C for 10 min, followed by quenching with glycine (final concentration 0.125 M) for 5 min. Cells were scraped on ice and centrifuged at 1,500 rpm for 5 min at 4 C. After washing once with PBS, cell pellets were resuspended gently in 1 ml of cold lysis buffer A (10 mM HEPES-KOH pH 7.5, 1 mM EDTA, 400 mM NaCl, 10% glycerol, 0.5% NP-40, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 3 mg/ml leupeptin, 0.1 mg/ml bacitracin, and 1 mg/ml a 2 -macroglobulin) followed by centrifugation at 13,000 rpm for 5 min at 4 C.
The resulting pellets were then resuspended in 1 ml cold lysis buffer A and sonicated with a W-220 sonicator (Heat Systems-Ultrasonics, Inc.). The chromatin solution was cleared by centrifugation at 13,000 rpm for 10 min at 4 C, and the supernatant (400 mg) was precleared for 2-4 hr with 80 ml of a 50% slurry of Protein A/G Sepharose beads (Amersham Biosciences). The Protein A/G Sepharose beads used for immunoprecipitation were preblocked overnight at 4 C with sheared salmon sperm DNA (0.3 mg/ml) and BSA (1 mg/ml) and then incubated with either a mixture of monoclonal anti-p53 monoclonal antibody supernatants (DO1 and 1801), anti-hCAS/CSE1L polyclonal antibodies (hCAS#689/#692), or anti-methyl-specific histone H3 antibodies from Abcam (Cambridge, UK) including trimethyl K4 Histone H3 (ab8580), dimethyl K9 Histone H3 (ab7312), or trimethyl K27 Histone H3 (ab6002). We predetermined amounts of anti-p53 antibodies necessary for p53 immunodepletion (>90%). Immunoprecipitations with the indicated antibodies were performed overnight at 4 C and immune complexes were eluted from the beads by adding 75 ml elution buffer (50 mM Tris-HCl pH 8.0, 1% SDS, 10 mM EDTA) and heating at 65 C for 10 min twice. Reverse crosslinking was performed by incubation of eluates or input chromatin at 65 C overnight. The DNA was then purified using the QIAquick PCR purification kit (Qiagen, Inc.), and PCR was performed using the Expand High Fidelity PCR system (Roche Applied Science, Indianapolis, IN). Approximately 1% of the input chromatin sample and 5% of the ChIP sample were used as template in each case. Reaction mixtures were initially melted at 94 C for 5 min followed by 27 cycles of 94 C for 30 s, 56 C for 1 min, 72 C for 1 min, and a final extension of 37 C for 7 min. Amplicons were visualized with ethidium bromide in 2.5% agarose gels. For the re-ChIP assay the procedure for preparing the sonicated lysate was the same as above, and then lysates were divided into two aliquots which were immunoprecipitated with p53 antibodies DO1/1801 or control IgG, coupled to protein A/G beads. One immunoprecipitate was treated as above to extract DNA (ChIP sample), while the other was incubated with re-IP elution buffer (50 mM Tris-HCl pH 8.0, 1% SDS, 1 mM EDTA, 1 mM DTT) at 37 C for 30 min twice and then diluted 1:10 in lysis buffer A followed by a second immunoprecipitation with anti-hCAS/CSE1L (hCAS #689/#692) or IgG antibodies (reChIP sample). The complex was eluted as described for the ChIP assay above, DNA was then purified using the QIAquick PCR purification kit, and PCR was performed using the Expand High Fidelity PCR system with the following conditions: mixtures were initially melted at 94 C for 5 min followed by 30 cycles of 94 C for 30 s, 56 C for 1 min, 72 C for 1 min, and a final extension of 72 C for 7 min for ChIP and 35 cycles for re-ChIP. Amplicons were visualized with ethidium bromide in 2.5% agarose gels. Primer sequences used for all ChIPs are described in the Supplemental Data.
Real-Time PCR For mRNA analysis, total RNA was isolated by RNeasy Mini Kit (QIAGEN Inc.) and was converted to cDNA using the Superscript III First Strand Synthesis System (Invitrogen). For either mRNA or ChIP experiments Real-time PCR was performed using TaqMan FAM-MGB probe and 23 TaqMan Universal PCR Master mix (Applied Biosystems, Foster City, CA) on an ABI Prism 7700 Sequence Detection system (Applied Biosystems) with b-glucuronidase (GUD) serving as an endogenous normalization control. Sequence Detection software was utilized for data analysis, and relative fold induction was determined by the comparative threshold cycle method using standard curves generated by plotting the observed CT value against the standard dilutions of positive control sample. In all experiments the average of three independent reactions is shown with error bars indicating standard deviation.
FACS Analysis
Cells were collected and pelleted at 1,500 rpm for 10 min and then resuspended in 300 ml of cold PBS followed by fixation with ice-cold methanol. At least 24 hr after fixation, cells were rehydrated in PBS for 30 min and then repelleted as above. Cells were then reconstituted in 1 ml of PBS containing 60 mg/ml propidium iodide and 50 mg/ml RNase A. Cell cycle profiles were obtained using a FACScalibur flow cytometer (BD Biosciences, San Jose, CA) and CellQuest software (BD Biosciences).
Sucrose Gradient Sedimentation and Mass Spectrometry
For sucrose gradient fractionation, either H1299 cells were infected with the indicated adenoviruses (p53 or Lac Z) for 20 hr or p53 was induced in the H24-14 derivative H1299 cell line by removal of tetracycline (Baptiste et al., 2002) . In either case cells were treated as for ChIP assay including lysis in buffer A, centrifugation, solubilization of pellets in buffer A, and sonication. For western blotting analysis and ChIP analysis as in Figures 1A-1D , 500 ml (5 mg/ml protein) of the sonicated extract was layered directly onto a gradient of 10%-40% (W/V) sucrose in 35 ml of IP buffer. Standard protein markers (100 mg each) of thyroglobulin (670 kDa), gamma-globulin (158 kDa), and bovine serum albumin (67 kDa) were layered onto parallel gradients. Ultracentrifugation was performed with a Beckman SW28 rotor at 24,000 rpm for 30 hr. Fractions were collected in volumes of 1.75 ml and aliquots taken for either immunoblotting (20 ml) or ChIP analysis (500 ml).
Supplemental Data
Supplemental Data include ten figures and Discussion and can be found with this article online at http://www.cell.com/cgi/content/full/ 130/4/638/DC1/.
